Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (Tarsus or the Company) has announced that it has entered into a definitive agreement, dated July 31, 2026, to acquire Alkeus Pharmaceuticals, Inc. (Alkeus), a privately held retinal disease‑focused biotechnology company developing gildeuretinol (ALK‑001), an investigational once‑daily oral therapy for Stargardt disease.

Latham & Watkins LLP advised Alkeus Pharmaceuticals in the transaction with a corporate team led by partners Scott Shean, Andrew Clark, and Shannon Cheng, with associates Amy Lutfi, Tim Schubert, Joanna Yam, Ariana Alemi, Ashley Nelson, and Emily Okabe. Advice was also provided on benefits, employment, and compensation matters by partner Michelle Carpenter, with associates Joseph Benedetto and Maddie Bober; on tax matters by partner Pardis Zomorodi, with associate Nolon Blaylock; on intellectual property and licensing matters by partner Steven Chinowsky and counsel Robert Yeh, with associate Taylore Williams; on regulatory matters by partner Elizabeth Richards, with associate Caroline Kessler; on healthcare and life sciences matters by partner Betty Pang; on representations and warranty insurance matters by partner Drew Levin; on antitrust matters by partners Amanda Reeves and Patrick English, with associate Kristen Previto; and on data privacy and cybersecurity matters by partner Heather Deixler, with associates Zac Alpert and Sarah Zahedi.